Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it plans to release its third quarter 2018 financial results after market close on Thursday, November 8, 2018.

Management will hold a conference call to review the company’s third quarter 2018 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-877-883-0383 (US/Canada) or 1-412-902-6506 (International), Participant Elite Entry Number 2105036, approximately ten to five minutes prior to start time.

About Senseonics

(NYSE American: SENS) is a medical technology company focused on the design, development and commercialization of transformative glucose monitoring products designed to help people with diabetes confidently live their lives with ease. From its inception, Senseonics has been advancing the integration of novel, fluorescence sensor technology with smart wearable devices. The Eversense® CGM System received PMA approval from the FDA for up to 90 days of continuous use and is available in the United States. The Eversense® CGM XL System received CE mark for up to 180 days of continuous use and is available in Europe. For more information on Senseonics, please visit www.senseonics.com.

INVESTOR CONTACTSenseonics Holdings, Inc.R. Don Elsey, 301-556-1602Chief Financial Officerdon.elsey@senseonics.com

Senseonics (AMEX:SENS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Senseonics Charts.
Senseonics (AMEX:SENS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Senseonics Charts.